Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association between the CYP2C9 polymorphism and the drug metabolism phenotype.

Clinical chemistry and laboratory medicine - 1 Jan 2004

Topić Elizabeta, Stefanović Mario, Samardzija Marina

Abstract excerpt

CYP2C9, an isoform of the cytochrome P450 enzyme, is involved in the metabolism of most of the drugs of choice for the treatment of thromboembolic disorders. Functional polymorphism is associated with two variant alleles (alleles *2 and *3) encoding CYP2C9 enzymes with a potentially different catalytic activity. The aim of the study was to determine the frequency of the CYP2C9 polymorphism in a representative...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Aryl Hydrocarbon Hydroxylases
Share to Croatia

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Hemorrhage

Share to Pharmacogenetics

Share to Thromboembolism

Share to Warfarin

Source

Identifiers

PMID: 15061384
DOI: 10.1515/CCLM.2004.014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association between the CYP2C9 polymorphism and the drug metabolism phenotype.PMID 15061384Read ↗

Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance.Semantic proximity Read ↗

CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis.Semantic proximity Read ↗

Analysis of CYP2C9 polymorphisms (*2 and *3) in warfarin therapy patients in Pakistan. Association of CYP2C9 polymorphisms (*2 and*3) with warfarin dose, age, PT and INR.Semantic proximity Read ↗

Effect of polymorphisms in the cytochrome P450 CYP2C9 gene on warfarin anticoagulation.Semantic proximity Read ↗

Impact of Genetic Polymorphisms in CYP2C9 and CYP2C19 on the Pharmacokinetics of Clinically Used DrugsSemantic proximity Read ↗

Cytochrome P450 polymorphisms are associated with reduced warfarin dose.Semantic proximity Read ↗

Prevalence of CYP2C9 and VKORC1 alleles in the Argentine population and implications for prescribing dosages of anticoagulants.Semantic proximity Read ↗

Association of CYP2C9 gene polymorphism with bleeding as a complication of warfarin therapy.Semantic proximity Read ↗

The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendationsSemantic proximity Read ↗

Analysis of CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G>A polymorphisms in a population from South-Eastern Europe.Semantic proximity Read ↗

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.Semantic proximity Read ↗

Pharmacogenetics aspects of oral anticoagulants therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.